 Phio Pharmaceuticals Corp NASDAQ: PHIO has presented new preclinical data for PH-894, a self-delivering RNAi compound targeting the bromodomain-containing protein 4 BRD4 The preclinical data exhibited that PH-894 inhibits tumor growth in both PD-1 inhibition responsive and PD-1. 